GNTA, STEM, ELN

Genta, StemCells Inc., and of course Elan, what is there to say about these three companies. Well on the one hand Genta has cost shareholders millions of dollars over the years, which is also true for Elan. Genta had a promising drug a couple years back called Genasense which was up for regulatory approval and was rejected and the stock went from around $18 to now $1.59. Then we have STEM, or StemCells Inc., they are just a speculative Stemcell company with lots of promise and no revenue and they run out of cash quickly...anyways I speculated on this stock and it made me alot of money during election time when this topic was hot. Then we have Elan. Elan is a good company with one drug behind it and if it doesnt get approved with this re-filing then it will suffer dearly...anyways I gotta run, but I am also gonna throw in IMCL ...They filed for regulatory approval of Erbitux for head and neck cancers which could generate millions more. prices now.... GNTA $1.59 price target $5.50..... STEM $5.53 price target $11...ELN $8.49 price target $22 pending on approval...hopefully.... and IMCL $29.80...price target....$45